Skip to main content

Table 4 α-Gal A activity in skin and kidney (nmol 4-MU/hr/mg protein)

From: Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies

 

Skin

Kidney

Baseline

Week 12

Week 24

Baseline

Week 12

Week 24

FAB CL-202 (NCT00283959) 1

2-0102 2

0.25

0.99

-

0.6

0.7

-

2-0103 2

0.65

34.05

-

0.8

4.7

-

2-0104 2

1.76

28.24

-

0.9

10.2

-

2-0202 2

6.97

105

-

4.4

29.9

-

FAB CL-203 (NCT00283933) 1

3-0301 2

0.92

3.08

2.6

0.4

-

1.2

3-0302 2

0.37

2.36

1.13

1.7

-

1.3

3-0303 2

0.82

2.97

1.37

0.8

-

1.0

3-RF01 2

37.29

139

133

21.6

-

157

3-RF03 2

1.22

22.77

41.88

1.5

-

14.7

  1. 1 Study number.
  2. 2 Patient ID.